Bridgebio Pharma vs Biocryst Pharmaceuticals
Biocryst Pharmaceuticals is the larger business, with $875m of revenue in fiscal 2025 against $502m for Bridgebio Pharma (1.7 times as much). Bridgebio Pharma grew faster (126.3% against 94.1%). Biocryst Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 30.2% against -144.4%.
| Latest fiscal year | Bridgebio PharmaBBIO, 2025 | Biocryst PharmaceuticalsBCRX, 2025 |
|---|---|---|
| Revenue | $502m | $875m |
| Revenue growth | 126.3% | 94.1% |
| Net income | −$725m | $264m |
| Operating margin | -104.2% | 39.0% |
| Net margin | -144.4% | 30.2% |
| Return on equity | — | — |
| Free cash flow | −$447m | $345m |
| Cash | $570m | $89.7m |
| Total debt | $2.01bn | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $48.3m | — |
| Employees | 834 | 435 |
| Market value | $14.64bn | $2.19bn |
| Price vs our value range | — | Below our value range |
| Moat score | 8 (Weak) | 46 (Moderate) |
| Insider trades, 12 months | 0 buys, 143 sales | 0 buys, 10 sales |